{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:17:26Z","timestamp":1789856246466,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16K18430"],"award-info":[{"award-number":["JP16K18430"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["16cm0106418h0001"],"award-info":[{"award-number":["16cm0106418h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17cm0106418h0002"],"award-info":[{"award-number":["17cm0106418h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.lungcan.2019.03.020","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T03:09:52Z","timestamp":1553224192000},"page":"107-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab"],"prefix":"10.1016","volume":"132","author":[{"given":"Jun","family":"Oyanagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8758-8980","authenticated-orcid":false,"given":"Yasuhiro","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-8532","authenticated-orcid":false,"given":"Koichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Teraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuninobu","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hayata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahomi","family":"Tokudome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lungcan.2019.03.020_bib0005","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"17","key":"10.1016\/j.lungcan.2019.03.020_bib0010","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2019.03.020_bib0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2019.03.020_bib0020","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.lungcan.2019.03.020_bib0025","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.lungcan.2019.03.020_bib0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2019.03.020_bib0035","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"25","key":"10.1016\/j.lungcan.2019.03.020_bib0040","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6280","key":"10.1016\/j.lungcan.2019.03.020_bib0045","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science (New York, N.Y.)"},{"issue":"7528","key":"10.1016\/j.lungcan.2019.03.020_bib0050","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.lungcan.2019.03.020_bib0055","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/annonc\/mdw016","article-title":"Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab","volume":"27","author":"Ferrucci","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2019.03.020_bib0060","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jtho.2017.10.030","article-title":"Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab","volume":"13","author":"Tanizaki","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2019.03.020_bib0065","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2019.03.020_bib0070","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.03.020_bib0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2019.03.020_bib0080","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2019.03.020_bib0085","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","article-title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients","volume":"28","author":"Sanmamed","year":"2017","journal-title":"Ann. Oncol."},{"issue":"Pt 23","key":"10.1016\/j.lungcan.2019.03.020_bib0090","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The tumor microenvironment at a glance","volume":"125","author":"Balkwill","year":"2012","journal-title":"J. Cell. Sci."},{"issue":"2","key":"10.1016\/j.lungcan.2019.03.020_bib0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1158\/2326-6066.CIR-13-0163","article-title":"Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab","volume":"2","author":"Yuan","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.lungcan.2019.03.020_bib0100","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/cas.13226","article-title":"Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma","volume":"108","author":"Yamazaki","year":"2017","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.lungcan.2019.03.020_bib0105","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.devcel.2005.09.008","article-title":"The structure of the follistatin: activin complex reveals antagonism of both type I and type II receptor binding","volume":"9","author":"Thompson","year":"2005","journal-title":"Dev. Cell"},{"key":"10.1016\/j.lungcan.2019.03.020_bib0110","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-018-0664-2","article-title":"Association of serum follistatin levels with histological types and progression of tumor in human lung cancer","volume":"18","author":"Zhang","year":"2018","journal-title":"Cancer Cell Int."},{"issue":"10","key":"10.1016\/j.lungcan.2019.03.020_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111398","article-title":"Follistatin is a novel biomarker for lung adenocarcinoma in humans","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.lungcan.2019.03.020_bib0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131453","article-title":"The BMP pathway participates in human naive CD4+ T cell activation and homeostasis","volume":"10","author":"Martinez","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.lungcan.2019.03.020_bib0125","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1027473","article-title":"IP-10\/CXCL10 attracts regulatory T cells: implication for pancreatic cancer","volume":"4","author":"Lunardi","year":"2015","journal-title":"Oncoimmunology"},{"issue":"22","key":"10.1016\/j.lungcan.2019.03.020_bib0130","doi-asserted-by":"crossref","first-page":"11064","DOI":"10.18632\/oncotarget.2519","article-title":"IP-10\/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival","volume":"5","author":"Lunardi","year":"2014","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.lungcan.2019.03.020_bib0135","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.184.3.981","article-title":"Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases","volume":"184","author":"Arenberg","year":"1996","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2019.03.020_bib0140","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00047-2016","article-title":"Pro-tumoural CXCL10\/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma","volume":"3","author":"Duruisseaux","year":"2017","journal-title":"ERJ Open Res."},{"issue":"21","key":"10.1016\/j.lungcan.2019.03.020_bib0145","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94296","article-title":"Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer","volume":"2","author":"Dominguez","year":"2017","journal-title":"JCI Insight"},{"issue":"15","key":"10.1016\/j.lungcan.2019.03.020_bib0150","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","article-title":"Tumor-produced Interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs)","volume":"22","author":"Alfaro","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2019.03.020_bib0155","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1158\/1078-0432.CCR-15-1823","article-title":"Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1beta, IL8, CXCL5, and Mip-1alpha","volume":"23","author":"Najjar","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"111","key":"10.1016\/j.lungcan.2019.03.020_bib0160","doi-asserted-by":"crossref","first-page":"111ra120","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1-PD1 axis converts human TH1 cells into regulatory T cells","volume":"3","author":"Amarnath","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2019.03.020_bib0165","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.trim.2005.12.001","article-title":"Role of platelet-derived chemokines (RANTES and ENA-78) after stem cell transplantation","volume":"15","author":"Nomura","year":"2006","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.lungcan.2019.03.020_bib0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fphar.2012.00023","article-title":"The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics","volume":"3","author":"Castor","year":"2012","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.lungcan.2019.03.020_bib0175","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2007-05-087403","article-title":"CCR1\/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation","volume":"110","author":"Choi","year":"2007","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.lungcan.2019.03.020_bib0180","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.lungcan.2019.03.020_bib0185","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.03.020_bib0190","series-title":"Prospective Multicenter Observational Study of Atezolizumab in Patients with Unresectable, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (J-TAIL; UMIN000037717)","author":"UMIN-CTR","year":"2019"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219303769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219303769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:05:22Z","timestamp":1777518322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219303769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":38,"alternative-id":["S0169500219303769"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.03.020","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}